Demographic and disease-specific characteristics
| N=55 | |
|---|---|
| Demographic characteristics | |
| Sex, male/female, N | 35/20 |
| Age, years (mean±SD) | 49.0±11.4 |
| Height, cm (mean±SD) | 174.2±9.3 |
| Weight (kg) | 84.9±20.1 |
| Body mass index, units (mean±SD) | 27.9±5.6 |
| Smokers, N (%) | 16 (29.1) |
| Characteristics of psoriatic skin disease | |
| Disease duration, years (mean±SD) | 15.2±15.4 |
| Psoriasis vulgaris, N (%) | 40 (72.7) |
| Other subtypes, N (%) | 15 (27.3) |
| Nail involvement, N (%) | 28 (50.9) |
| Scalp involvement, N (%) | 16 (29.1) |
| PASI score, units (mean±SD) | 6.2±8.0 |
| DLQI score, units (mean±SD) | 6.3±6.1 |
| Musculoskeletal symptoms | |
| Tender joint count 68, N (mean±SD) | 1.6±2.9 |
| Tender joint count >0, N | 21 |
| Swollen joint count 66, N | 0 |
| Presence of enthesitis, N | 0 |
| Presence of dactylitis, N | 0 |
| VAS pain, mm (mean±SD) | 25.6±27.0 |
| VAS global, mm (mean±SD) | 23.0±25.5 |
| HAQ score (units, mean±SD) | 0.4±0.5 |
| Laboratory parameters | |
| C reactive protein, mg/L (mean±SD)* | 3.8±4.6 |
| ACPA positive, N | 0 |
| RF positive, N (%)† | 4 (7.3) |
| Treatment modalities | |
| No current treatment, N (%) | 15 (27.3) |
| Topical treatments N (%) | 25 (45.5) |
| Fumaric acid N (%) | 11 (20.0) |
| Methotrexate and other systemic agents N (%) | 9 (16.4) |
| TNF inhibitors N (%) | 3 (5.5) |
| IL-12/IL-23 inhibitors N (%) | 1 (1.8) |
*Normal value <5 mg/mL.
†All four patients had low-titre RF (<50 IE/mL).
ACPA, anticyclic citrullinated peptide antibodies; DLQI, Dermatology Life Quality Index; HAQ, health assessment questionnaire; IL, interleukin; PASI, psoriasis area severity index; RF, rheumatoid factor; TNF, tumour necrosis factor; VAS, visual analogue scale.